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Purpose: To determine the prevalence of cancer-related fatigue syndrome (CRFS) in a pop-
ulation of disease-free breast cancer survivors and to investigate the relationship between
CRFS and clinical variables.
Patients and methods: Women (200) were recruited. All participants were between 3 months
and 2 years after completion of primary therapy for breast cancer andwere disease free. Sub-
jects completed a diagnostic interview for CRFS and structured psychiatric interview. Partic-
ipants also completed quality of life, mood and fatigue questionnaires, and provided a blood
sample for haematological and biochemical analysis and a 24-h urine specimen for cortisol
estimation. Subjects wore a wrist actigraph for 7 days to measure activity and sleep.
Results: Sixty women (30% of participants) were found to fulfil the criteria for CRFS. There
were statistically significant differences between fatigued and non-fatigued women with
respect to fatigue severity (p < 0.01), mood (p < 0.01) and quality of life scores (p < 0.05). There
were significant differences in blood variables including raised total white cell count and
lower sodium (all p < 0.02). There was no difference in the 24 h urinary free cortisol levels.
Actigraphic data demonstrated significant differences in sleep quality and disturbance,
but not in overall levels of daytime activity or circadian rhythm.
Conclusion: CRFS affects 30% of women after breast cancer treatment and has significant
effects on quality of life and mood. There is some evidence that CRFS is related to sleep dis-
turbance or to a persistent inflammatory or immune response.
 2008 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Cancer-related fatigue (CRF) is a common symptom that can
occur both in patients during treatment for breast cancer1
and in disease-free survivors.2 However, the prevalence of fa-
tigue can vary with how it is measured.3,4 In an effort to stan-
dardise the classification of fatigue, Cella and colleagues have
developed a set of diagnostic criteria that must be fulfilled for
an individual to be considered a ‘case’ of CRF.5 To fulfil these CC BY-NC-ND license.
45; fax: +44 (0)208725353
ne).diagnostic criteria the subject must have experienced at least
6 of 11 fatigue-related symptoms onmost days or every day for
2 weeks in the previous month. At least one of these symp-
toms must have been ‘significant fatigue, lack of energy, or
an increased need to rest’. The fatigue needs to be sufficiently
severe to have had an impact on daily life. There must be evi-
dence from the history, physical examination or laboratory
findings that the symptoms are a consequence of cancer or
cancer therapy. Finally, the fatigue should not be ‘primarily a8.
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jor depression, somatisation disorder or delirium’. Most of
these criteria can be assessed using Cella and colleagues’short
diagnostic interview.5 However, in order to systematically as-
sess patients with co-morbid psychiatric disorders it is neces-
sary to also perform a psychiatric assessment using an
instrument such as the structured clinical interview for the
diagnostic and statistical manual of mental disorders (SCID).
This approach to defining ‘cases’ of CRF syndrome is similar
to the approach used to diagnose cases of chronic fatigue syn-
drome (CFS),6 which potentially has some similarities with
CRF in this population.7 The diagnostic criteria permit patients
to have both cancer-related fatigue syndrome (CRFS) and a co-
morbid psychiatric diagnosis8 provided that the fatigue is not
primarily due to the psychiatric disorder. It has been sug-
gested that a decision can be made about the causation of
the fatigue based upon the timing of the onset of the symptom
and the presence or absence of other fatigue-related attributes
(e.g. diurnal variation, strength of cognitive symptoms). How-
ever, in practice it can be extremely difficult to determine
whether the fatigue should primarily be attributed to the psy-
chiatric disorder or to the cancer diagnosis/treatment.
The diagnostic criteria for CRF syndrome have been used
successfully in previous studies of breast cancer patients. A
small study by Young et al.9 examined patients (n = 69) for
an average of 6 months after breast cancer treatment. The
prevalence of CRF syndromewas 19%. Those who met the cri-
teria had significantly more fatigue-related symptoms, mood
disturbance and quality of life disruption than those who did
not. However, patients in this study did not undergo a rigor-
ous psychiatric assessment, making it unclear whether some
of the patients with CRF syndrome actually had a co-morbid
psychiatric disorder. Andrykowski et al.10 conducted a much
larger study (n = 288) to examine the reliability of the CRF cri-
teria in an on-treatment breast cancer population and in-
cluded the SCID interview to assess psychiatric morbidity.
This study demonstrated an increase in the prevalence of
CRF syndrome from 10% at baseline to 26% post treatment.
This post-treatment prevalence included patients with psy-
chiatric co-morbidities including major depression.
A limitationof both theseprevious studies is thatwhile they
examined a number of subjective symptoms and demographic
data neither study attempted to correlate CRF with biological
variables or objective measure of activity. The prevalence of
CRF syndrome in disease-free women months to years after
completion of therapy has not been reported previously.
A recent systematic review by Prue and colleagues3 dem-
onstrated not only wide variation in the measurement of
CRF but also limited evidence of its association with mood
disturbance and other quality of life co-variables. This is in
part due to the lack of an agreed definition of fatigue and
the subjective nature of its measurement.
Despite extensive research on patho-physiological causes
of CRF, the causes are poorly understood.11 Anaemia is fre-
quently considered to be a cause of fatigue in cancer pa-
tients,12 and there is evidence that correction of anaemia
leads to improvement in fatigue among patients undergoing
chemotherapy.13 There is a dearth of studies to investigate
the relationship between fatigue and other biochemical or
inflammatory markers. It has been suggested that theremay be similarities between the mechanisms of fatigue in pa-
tients with CRF syndrome and patients with CFS.7 Physical
deconditioning has been proposed as one of the key factors
in perpetuating fatigue in patients with CFS.14 It has been sug-
gested that fatigue in cancer patients similarly may be due to
deconditioning following a period of inactivity,12–15 but very
few studies have specifically tested this hypothesis. There is
some evidence to suggest that patients with CFS demonstrate
a disruption of the hypothalamic pituitary adrenal axis
(HPA).16,17 However, very few studies have investigated
whether similar defects exist in patients with CRF.
This current study examines the hypotheses that CRFS in
this population is related to disruption of the HPA axis and re-
duced physical activity. We hypothesised that patients with
CRFS would have alterations in 24-h urinary free cortisol
and objective evidence of decreased physical activity and dis-
rupted sleep (as measured by actigraphy). In order to evaluate
the hypotheses that fatigue in cancer survivors is due to
anaemia, metabolic disturbances (such as renal or liver
impairment) or sub-clinical hypothyroidism, we also obtained
routine blood samples for analysis. Additional assessments
were undertaken to explore the relationship between fatigue
severity and the severity of other symptoms (such as pain,
nausea or psychological distress).
The specific aims of the study were therefore: (1) to iden-
tify the prevalence of CRF syndrome in disease-free breast
cancer survivors and (2) to identify clinical, psychosocial, bio-
logical and objective activity variables previously hypothe-
sised to be associated with CRF syndrome.
2. Patients and methods
Participants were women with stage I–IIb breast cancer, trea-
ted with primary therapy between 3 months and 2 years pre-
viously. Clinically disease-free women were recruited at St
George’s NHS Trust London over a 2-year period by one re-
searcher (S.A.). Inclusion criteria were age at least 18 years;
histologically proven breast cancer; completed all treatment
modalities at least 3 months and not more than 2 years pre-
viously; and concurrent hormone use was allowed. Exclusion
criteria included pregnancy; co-existing cancer diagnosis; evi-
dence of recurrent disease and confusion or dementia.
Approval for the study was given by the Wandsworth Re-
search Ethics Committee and by St George’s NHS Trust Re-
search and Development Committee.
Eligible women were identified from the clinic list 14 days
prior to their appointment and were posted an introductory
letter and an information sheet. Women who declined to par-
ticipate in the study were asked if they would be willing to
complete a short fatigue questionnaire.
2.1. Assessments
Participants completed the following assessments:
2.1.1. Blood tests (taken in the clinic at the time of the first
appointment)
Full blood count; urea and electrolytes; liver function tests;
bone profile; thyroid function; glucose and C-reactive protein
(CRP).
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attending the second assessment 1 week later)
A 24-h collection for estimation of urinary cortisol.
2.1.3. Actigraphy (completed at home after the initial
assessment over a 1 week period)
Participants were asked to wear a wrist actigraph for a contin-
uous period of 7 days. The actigraph used was the octagonal
motion loggerTM (Ambulatory Monitoring Incorporated, Ards-
ley, NY, USA) and associated software (Action W). Actigraphs
convert kinetic energy from wrist movements into electrical
energy proportional to activity. Information is recorded at
one minute epochs and stored within the watch prior to
downloading. This technique has been successfully used be-
fore in fatigued cancer inpatients.18 Actigraphic data are ana-
lysed during four major intervals: down intervals – the time
spent in bed trying to sleep; up intervals – the time between
successive down intervals; 0–0 intervals – the time from sleep
onset to sleep offset and 24-h intervals – used to determine
circadian rhythm.
2.1.4. Questionnaires (completed in the clinic at the.second
assessment 1 week after the initial assessment)
(1) Functional assessment of cancer therapy – fatigue sub-
scale (FACT F)19: This is a 13-item tool validated in can-
cer patients and used widely in clinical studies for
fatigue interventions.20
(2) Bidimensional fatigue scale (BFS): This is a 11-item
scale with seven items assessing physical fatigue and
four items assessing mental fatigue.21 It was developed
for use in community surveys, but has subsequently
been successfully used to measure fatigue in cancer
populations.22,23
(3) Fatigue catastrophising scale (FCS): This is a 10-item
scale used in a previous study of breast cancer patients24
to measure a particular aberrant coping style.
(4) Work and social adjustment scale (WAS): This is a five-
item scale which measures the functional impact of
fatigue.25
(5) Hospital anxiety and depression scale (HADS): This is a
14-item scale with seven items on anxiety and seven
items on depression.26 It is used extensively in clinical
trials and has been used by our group previously in fati-
gue assessment studies.27
(6) European Organisation of Research and Treatment of
Cancer Quality of Life questionnaire EORTC QLQ 30:
This is a 30-item scale with five functional scales, three
symptom scales and a global quality of life score.28
(7) EORTC breast module (BR 23): This is a 23-item scale
which is validated for use in breast cancer patients.29
It has four dimensions – body image, sexual function-
ing, sexual satisfaction and future perspective.
2.1.5. Diagnostic interview for cancer-related fatigue
(conducted with SCID by SA in the clinic at the first assessment)
This interview determines whether the participant meets the
four criteria for a diagnosis of CRF syndrome. Criterion A: thepresence of significant fatigue for 2 weeks in the preceding
month and the presence of at least 5 of 10 other fatigue-re-
lated symptoms. Criterion B: the fatigue has a significant ef-
fect on work or self-care. Criterion C: the fatigue symptoms
are a consequence of cancer or cancer therapy. Criterion D:
the symptoms are not primarily a consequence of a co-mor-
bid psychiatric disorder. It should be noted that although
the diagnostic criteria permit patients to have a co-existing
psychiatric disorder provided it is not judged to be the main
cause of the fatigue, we felt that this would introduce an
unacceptable level of subjectivity into the diagnosis. For this
reason, a robust categorisation was employed and any pa-
tients with potentially fatiguing psychiatric disorders (includ-
ing phobias and anxiety states) were excluded from the
diagnosis of CRFS.
2.1.6. Structured clinical interview for the diagnostic and
statistical manual (DSM) – IV (SCID)
The SCID provides a method for obtaining DSM-IV diagnoses.
The procedure has been successfully used in previous studies
examining CRF syndrome.10,30 Training in the use of the SCID
was supervised by two consultant psychiatrists. All inter-
views were conducted by the same person (S.A.).
3. Statistical considerations
The effect size for between-group differences was calculated
for a sample of 200 women, and was based on previous re-
search conducted in the CFS population.31 It was estimated
that we would identify 100 women in each category (cases
versus controls) and this would allow us to detect an effect
size of 0.52 at 95% power (two-sided 5% significance). The
power was subsequently revised down to 80% during the
study, which still allowed us to examine between-group dif-
ferences with at least 60 women in each category. The be-
tween-group analysis was conducted using Mann–Whitney
tests with comparisons between median scores because of
the non-normal distribution of the data. The level of signifi-
cance was set at p < 0.05; no adjustment was made for multi-
ple comparisons. This was an exploratory and hypothesis
generating study and p-values are reported and interpreted
in this context.
4. Results
Women (292) were eligible for participation, with 208 women
consenting. The demographics and questionnaire (BFS only)
responses of the non-participants (n = 84) were recorded, and
are shown in Table 1. The main reasons for non-participa-
tion included other medical conditions, work commitments
and extra visits required. There were no significant differ-
ences in treatment regimen, stage at diagnosis between par-
ticipants and non-participants. However, there was a
significant difference in fatigue scores, with non-partici-
pants scoring lower on the BFS – indicating less fatigue in
this group. Non-participants also had a significantly higher
mean age. Eight women did not proceed to interview for a
variety of reasons and 200 women completed the full inter-
view process. Subjects had a mean age of 58 years (SD
Table 1 – Demographic data and fatigue scores for participants and non-participants
Variables Participants Non-participants p-Value
Mean Standard deviation Mean Standard deviation
Age in years (range) 57.96 (29–89) 12.3 66.61 (35–92) 12.5 <0.01*
Time post treatment in months 9.93 5.6 11.13 5.4 0.10
Bidimensional fatigue scale (BFS) score total 13.69 8.6 9.29 7.42 0.009*
BFS score physical 9.51 5.90 6.70 5.19 0.027*
BFS score mental 4.18 3.31 2.58 2.86 0.108
* p-Value < 0.05.
Table 2 – Different frequencies of treatment type and lymph node status in cases versus controls
Controls Cases of cancer-related fatigue syndrome (CRFS) p-Value
Frequency Percent (%) Frequency Percent (%)
Surgical procedure
Breast conservation (lumpectomy) 55 52.9 31 51.7 0.88
Modified radical mastectomy 35 33.7 21 35 0.86
Mastectomy and reconstruction 14 13.5 8 13.3 0.98
Adjuvant treatment
Chemotherapy 50 48.1 34 56.7 0.29
Radiotherapy 74 71.2 48 80 0.21
Hormonal therapy 91 87.5 47 78.3 0.12
Lymph node status
Lymph node negative 69 66.3 39 65 0.86
Table 3 – Comparison of biochemical, haematological and endocrine indices
Variable Laboratory reference range Mean control SD Mean CRFS SD p-Value
Haematology data
Haemoglobin (g/dl) 12–16 13.09 0.94 13.24 0.991 0.510
White cell count (No. · 109/L) 4 –11 5.86 1.60 6.64 1.91 0.021*
Neutrophil (No. · 109/L) 1.7–8.0 3.67 1.34 4.21 1.66 0.048*
Lymphocyte (No. · 109/L) 1.0–4.0 1.57 0.53 1.72 0.64 0.249
Monocyte (No. · 109/L) 0.24–1.1 0.45 0.13 0.5 0.15 0.052
Eosinophil (No. · 109/L) 1.0–0.8 0.14 0.11 0.16 0.10 0.051
Basophil (No. · 109/L) 0.0 0.01 0.03 0.02 0.04 0.041*
Platelet (No. · 109/L) 150–450 249 59.68 267 65.36 0.093
Biochemistry data
Sodium (mmol/L) 135–145 139.97 2.29 139.15 2.41 0.018*
Potassium (mmol/L) 3.5–4.7 4.41 0.43 4.36 0.34 0.744
Urea (mmol/L) 2.5–8.0 4.77 2.00 4.52 1.41 0.650
Creatinine (lm/L) 60–110 74.36 21.81 70.22 15.22 0.225
Glucose (mmol/L) 3.0–6.0 5.27 0.95 5.95 2.67 0.415
C Reactive protein (mg/dL) 0–7.5 2.74 3.55 3.91 4.24 0.015*
Uncorrected calcium (mmol/L) 2.18–2.47 2.36 0.11 2.43 0.40 0.208
Phosphate (mmol/L) 0.75–1.50 1.18 0.16 1.23 0.19 0.062
Alkaline phosphatase (IU/L) 30–100 60.81 19.99 68.48 23.94 0.024*
Alanine transaminase (IU/L) 0–40 23.31 16.89 25.32 12.00 0.016*
Bilirubin (lmol/L) 0–17 11.68 3.39 11.03 3.49 0.104
Albumin (g/L) 35–48 39.41 4.47 38.80 4.70 0.261
GGT (IU/L) 0–30 28.15 14.20 33.46 21.57 0.235
Endocrine data
TSH (mU/L) 0.4–4.0 2.01 1.17 2.96 7.68 0.753
Free T4 (pmol/L) 12–24 14.82 2.22 15.23 2.94 0.504
Urinary free cortisol (nmol/24 h) 0–290 159.27 95.17 164.32 64.63 0.305
* p < 0.05.
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Table 4 – Differences in between-group questionnaire data
Variable Mean controls SD Mean CRFS SD p-Value
Function scales
Physical functioning 87.37 13.266 65.42 20.807 <0.001*
Role functioning 91.35 15.576 61.02 24.095 <0.001*
Emotional functioning 85.42 13.530 67.23 22.470 <0.001*
Cognitive functioning 84.13 16.808 55.65 28.636 0.36
Social functioning 93.27 13.645 74.01 26.492 <0.001*
Total of FCS 12.46 3.223 17.70 6.939 <0.001*
Total of WAS 3.58 5.182 16.68 10.336 <0.001*
Total of FACT F 46.00 6.65 26.00 10.39 <0.001*
Total of BFS 8.85 6.16 18.97 7.26 <.01*
Symptom scales
Fatigue 21.47 15.112 54.07 23.187 <0.001*
Nausea/vomiting 3.85 9.916 5.00 11.191 0.18
Pain 12.66 20.179 36.11 36.069 0.19
Dyspnoea 9.29 17.661 26.11 31.944 0.21
Insomnia 25.00 25.757 60.00 30.56 0.003*
Appetite loss 6.41 16.797 15.56 27.078 0.001*
Constipation 10.26 19.195 16.67 27.787 <0.001*
Diarrhoea 4.49 13.185 8.33 20.005 0.12
Financial difficulties 7.05 18.966 19.44 31.469 0.04*
Body image 83.98 19.964 67.08 331.136 0.001*
Sexual functioning 23.79 24.655 11.39 20.237 <0.001*
Sexual enjoyment 60.42 28.893 38.60 31.940 0.001*
Future perspectives 68.93 28.107 53.89 33.102 0.03*
Breast systemic therapy side effects 12.76 10.313 28.10 19.677 0.004*
Breast symptoms 12.54 13.501 24.58 24.036 <0.001*
Arm symptoms 15.86 17.367 25.18 26.819 <0.001*
Upset by hair loss 16.67 21.681 66.67 43.363 0.004*
Mood questionnaires
HAD-T score 6.74 4.921 12.23 6.487 <0.001*
Total of HAD-D 2.55 2.496 5.58 3.341 <0.001*
Total of HAD-A 4.19 3.315 6.65 15.045 <0.001*
Global health status 81.09 16.797 56.07 22.787 <0.001*
* p < 0.05.
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Overall, 60 participants met the criteria for CRF and were
deemed cases, 104 did not meet the criteria and were con-
sidered to be the ‘control group’ and 36 participants were
deemed to have a co-morbid psychiatric diagnosis that
may have resulted in fatigue and were not included in any
further analysis in this report.
4.1. Characteristics of cases versus controls
4.1.1. Treatment and demographic variables (Table 2)
There was no statistical difference in age (controls 57.45 years
[SD 12.77], cases 59.17 years [SD 11.52]; p = 0.94) or time since
treatment (controls 9.99 months [SD 5.92], cases 9.80 months
[SD 5.52]; p = 0.41). There was also no statistically significant
difference in type of surgery, adjuvant treatment regimen or
lymph node status between the groups.
4.1.2. Haematological, biochemical and endocrine indices
(Table 3)
There were significant between-group differences in a num-
ber of these investigations. The most notable were the signif-
icant differences in total white cell count (controls 5.86
counts · 109 [SD 1.6], cases 6.64 · 109 [SD 1.91]; p = 0.021), so-dium (controls 139.97 mmol/L [SD 2.29], cases 139.15 mmol/L
[SD 2.41]; p = 0.018) and CRP (controls 2.74 mg/dL [SD 3.55],
cases 3.91 mg/dL [SD 4.24]; p = 0.015). There were also signifi-
cant differences in some of the liver function tests. No differ-
ence was found in thyroid function tests or 24 h urinary free
cortisol.
4.1.3. Questionnaire data (Table 4)
There were significant differences on all fatigue scales with
cases scoring significantly higher than controls. Cases of
CRF scored significantly higher on the FCS and on the WAS
indicating greater catastrophising about fatigue and a greater
impact of fatigue on work and social adjustment. Cases also
scored higher on the anxiety and depression subscales of
the HADS – indicating greater sub-threshold mood distur-
bances. There were significant differences on a number of
the quality of life domains in both the EORTC QLQ 30 and
BR 23. The most important exception to this was a lack of sig-
nificant difference in cognitive functioning scores on the QLQ
30.
4.1.4. Actigraphic data (Table 5)
There were only a few significant differences in actigraphic
data between the groups. There was no difference in mean
Table 5 – Between-group actigraphic data differences
Variable Mean controls SD Mean CRFS SD p-Value
Down activity measurement
Down activity mean 39.75 26.712 42.33 26.712 0.219
Down activity median 21.48 30.219 23.93 26.159 0.077
Down activity SD 47.01 14.879 50.21 14.948 0.351
Down wake minutes 55.85 49.590 70.89 50.014 0.047*
Down sleep minutes 318.76 107.165 293.07 95.112 0.177
Down % sleep 75.03 17.457 72.40 15.893 0.167
Down sleep efficiency 92.88 5.860 90.05 8.545 0.056
Down sleep latency 26.66 23.216 63.60 36.01 0.052
Up activity measurement
Up activity mean 174.33 40.214 179.02 38.134 0.521
Up activity median 186.45 51.594 194.63 51.962 0.278
Up activity SD 83.79 13.497 83.51 11.365 0.889
Up wake minutes 637.04 245.729 614.88 211.213 0.800
Up sleep minutes 71.57 111.7 62.23 92.393 0.769
Up % sleep 13.01 11.010 12.48 11.912 0.564
Up activity index 93.35 7.158 93.39 10.01 0.533
Up wake episodes 7.12 8.627 6.14 4.535 0.873
0–0 activity measurement
0–0 activity mean 35.17 32.10 177.92 1085.293 0.165
0–0 activity median 2.74 9.81 3.47 5.30 0.063
0–0 activity SD 26.06 12.574 27.77 9.021 0.072
0–0 wake minutes 31.35 73.218 35.43 33.714 0.061
0–0 sleep minutes 314.21 108.356 287.67 96.057 0.179
0–0 % sleep 80.53 17.929 79.07 18.445 0.230
0–0 sleep efficiency 92.92 5.877 89.64 9.739 0.051
0–0 wake after sleep 28.62 24.981 40.15 37.582 0.086
0–0 mean wake episodes 4.13 4.321 4.85 0.89 0.009*
0–0 longest Wake episode 11.24 14.272 15.26 12.429 0.013*
* p < 0.05.
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mean activity. There were some statistically significant differ-
ences in the sleep period intervals reflecting the quality and
nature of actual sleep as opposed to time spent in bed trying
to sleep. There were significant differences in mean wake epi-
sodes and median longest wake episode occurring during the
true sleep period.
5. Discussion
This study provides further evidence to support the useful-
ness of Cella and colleagues’ diagnostic criteria for CRF in a
population of breast cancer survivors. There was, however,
only one interviewer (SA) and so our study cannot examine
any inter-interviewer reliability of the diagnostic criteria.
Using a strict application of these criteria, we established
the prevalence of CRF syndrome in our sample to be 30%. This
figure is in keeping with the data from the only two previous
studies to use the diagnostic criteria in breast cancer patients.
Andrykowski and colleagues reported a post-treatment prev-
alence of 26%10 andWhite and colleagues a prevalence of 19%
in their smaller sample.9 The figure from our study is higher
despite excluding participants with a potentially fatiguing
psychiatric co-diagnosis. The women who were studied in
our investigation had completed adjuvant therapy up to 2
years previously, and may have experienced longer term
treatment toxicities than have been previously described.While our figure is higher than those of the other two stud-
ies to have used the diagnostic criteria, it is more conservative
than many prevalence figures reported in the literature.32,33
Some studies have simply reported prevalence figures for fa-
tigue based on the number of women reporting at least some
degree of the symptom.34,35 Since fatigue is a common symp-
tom in the general (non-cancer) population, this approach is
likely to over-estimate the prevalence of clinically significant
fatigue. The validity of the diagnostic criteria is supported by
the large and significant differences that we found in virtually
all the quality of life domains. Women identified as ‘cases’ of
CRFS reported lower levels of functioning and higher levels of
symptom severity. The most notable exception to this was on
the cognitive function subscale of the EORTC QLQ 30. This is
despite a large effect size, and may be because of the limita-
tions of the EORTC cognitive subscale to fully assess cognitive
function.36
The HADS data demonstrated a higher level of anxiety and
depression in the cases, but not at a level required to meet the
cut-off for a psychiatric diagnosis. The significance of these
results is unclear – while CRF and depression may overlap,
they are two separate phenomena in this population.37,38 It
has been demonstrated previously that CRF is associated with
greater psychological distress in women treated for breast
cancer.37 It is possible that this distress may manifest itself
as a lower symptom threshold in the cases of CRF. In keeping
with previous work, we found that women who tended to
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of life.24,34
We found no evidence to support our hypothesis that wo-
men who were cases of CRFS would be less active than con-
trols. Most studies seem to suggest that exercise is
beneficial in terms of improving physical performance,39,40
but there is much less evidence to suggest that exercise actu-
ally improves the symptom of subjective fatigue.39 Three41–43
previous small studies have all found no correlation between
fatigue severity in cancer patients and objective measures of
activity. Our current study is by far the largest to have objec-
tively investigated whether patients who complain of subjec-
tive fatigue are actually less active than non-fatigued
subjects. Our results suggest that physical deconditioning is
not the explanation for fatigue in breast cancer survivors. Fur-
thermore, they suggest that any beneficial effects of exercise
in reducing subjective fatigue in this group are likely to be
‘indirect’ (e.g. secondary to the beneficial effects of exercise
on mood, immune functioning or sleep).
We found some evidence that women who were cases of
CRF syndrome reported more insomnia than controls and this
was supported (to some extent) by the objective actigraphic
data. Previous actigraphic studies have also reported a corre-
lation between sleep disturbance and fatigue in cancer pa-
tients.41–43 In our study the observed sleep disturbances
were relatively mild and cannot explain all the associated
CRF symptoms. Savard and colleagues44 have reported that
while cognitive-behavioural therapy is an effective treatment
for insomnia in breast cancer patients it does not significantly
improve fatigue. The relationship between sleep and fatigue
therefore requires further characterisation.
Most of the laboratory variables that we assessed were not
significantly different between cases or controls. In particular,
the haemoglobin and thyroid function tests (both significant
potential causes of fatigue45,46) were not significantly differ-
ent between the cases and the controls. It is important to note
that approximately 10% of the participants were anaemic
(Hb < 12 g/l) – although none had haemoglobin less than
10 g/l. The total white cell count and CRP were significantly
higher in the cases of CRF (although mean levels still fell
within the normal range). These results hint at a prolonged
immune/inflammatory response in women with persistent
fatigue. A previous systematic review has found evidence of
raised IL-1, IL-6 and neopterin in fatigued cancer patients.47
Unfortunately, the resources of this project did not allow a
more sophisticated assessment of inflammatory or immune
mediators, but this should be the focus of future studies in
this area. The clinical significance of the recorded differences
in electrolyte and liver function tests remains unclear. These
could be attributable to disturbances post chemotherapy,
alterations related to drugs (including alcohol intake) or
linked to the pathophysiology of fatigue.
Alterations in HPA axis functioning have been identified in
a number of studies in patients with CFS.48 Bower et al.49
demonstrated a flattening of the diurnal cortisol rhythm,
but no gross disruption of the HPA axis, in 13 fatigued women
after completion of breast cancer treatment. Bower measured
salivary cortisol at three time points over a 48-h period. The
different methods make direct comparison difficult. However,
our finding that urinary free cortisol was no different betweencases and controls is a useful negative and suggests that there
is no gross peripheral disruption to the HPA axis in fatigued
cancer survivors. However, urinary cortisol estimation is only
a measure of basal secretion rates. A fuller assessment of the
HPA axis would require the use of stimulation tests which
were beyond the resources of the current study.
Our study evaluated a large number of different variables,
and caution is required in not allocating toomuch significance
to any given finding. As this was an exploratory study we did
notmake any adjustment formultiple comparisons in our sta-
tistical analysis and our results must be interpreted with this
caveat. Our study lacked an age-matched non-cancer control
group. This is important as fatigue has a baseline prevalence
in the population which increases with age.21 However, the
prevalence of CRF was still significantly higher in this popula-
tion even after adjusting for a baseline population level.4 It is
worth noting that participants in our studywere actuallymore
fatigued than non-participants. Consequently, it is possible
that our study has somewhat over-estimated the prevalence
of CRFS. This is perhaps surprising as it has often been as-
sumed that women who are more fatigued will be less likely
to participate in research. As far aswe are aware this is the first
study to have assessed the fatigue scores of non-participants.
In conclusion, this study represents a detailed assessment
of the prevalence of CRF in breast cancer survivors (without
psychiatric co-morbidity). We found that 30% of women were
severely affected by fatigue and that this was associated with
a significantly worse quality of life, lower self-reported func-
tional abilities and higher symptom severity. We found no
evidence to support the hypothesis that CRF syndrome is re-
lated to physical deconditioning. We found subtle distur-
bances in immune and inflammatory markers, overall
quality of life, mood and sleep quality in women with CRF
syndrome. Future work should focus on further examination
of the immune/inflammatory response and HPA axis to iden-
tify specific causes of CRF that can be targeted for treatment
in clinical practice. The potential overlap of this group with
the CFS population may also provide directions for future re-
search and management.
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